元素标记免疫分析联合电感耦合等离子体质谱检测:能否用于临床实验室?
该研究以癌胚抗原(CEA)为模型,按照CLSI标准系统评估了元素标记免疫分析联合ICP-MS检测的分析性能,并与电化学发光免疫分析法(ECLIA)对比了469例临床样本。结果表明该方法的测量范围、检出限、精密度、交叉反应、回收率、线性、干扰等性能均满足CLSI要求,与ECLIA相关性好且无显著差异,证明其临床可转移性和应用潜力。
要点
- 该方法测量范围1-900 ng/mL,检出限0.83 ng/mL,参考区间0-4.442 ng/mL。
- 高浓度样本批间和批内精密度分别为4.67%和5.38%,低浓度样本分别为9.27%和17.64%。
- 与ECLIA对比469例临床样本,相关性0.9878,无显著差异(p=0.6666)。
核心结论
- 基于ICP-MS的免疫分析成功建立,分析性能满足CLSI要求,充分证明其临床可转移性和应用潜力。
研究设计与样本
- 选择癌胚抗原(CEA)作为分析物,按照临床和实验室标准协会(CLSI)标准对提出的方法进行系统评估。
- 使用新方法分析469例临床样本,并与电化学发光免疫分析法(ECLIA)进行比较。
主要发现
- 测量范围为1-900 ng/mL,检出限为0.83 ng/mL。
- 高浓度样本的批间和批内精密度分别为4.67%和5.38%,低浓度样本分别为9.27%和17.64%。
- 不同抗原的交叉反应率小于0.05%,回收率在94%至108%之间。
- 线性评估中所有稀释度的百分比偏差小于12.5%,不同物质引起的干扰偏差小于10%。
- 参考区间为0-4.442 ng/mL;与ECLIA方法对比,相关性为0.9878,方法间无显著差异(p=0.6666)。
关键数值与推荐
- 测量范围1-900 ng/mL,检出限0.83 ng/mL。
- 高浓度样本批间精密度4.67%、批内精密度5.38%;低浓度样本批间精密度9.27%、批内精密度17.64%。
- 交叉反应率小于0.05%,回收率94%-108%,线性稀释百分比偏差小于12.5%,干扰偏差小于10%。
- 参考区间0-4.442 ng/mL;与ECLIA相关性0.9878,p=0.6666。
临床怎么用
- 该ICP-MS免疫分析性能符合CLSI要求,与ECLIA结果一致性良好,可考虑用于临床实验室CEA检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction Element-tagged immunoassay coupled with inductively coupled plasma-mass spectrometry (ICP-MS) detection has the potential to revolutionize immunoassay analysis in clinical detection; however, a systematic evaluation with the standard guidelines of the assay is needed to ensure its performance meets the requirements of the clinical laboratory. Methods Carcinoembryonic antigen (CEA) was chosen for analysis using the proposed method. A systematic evaluation of the proposed assay was carried out according to the Clinical and Laboratory Standards Institute (CLSI). The 469 clinical samples were analyzed using the new method and compared with the electrochemiluminescent immunoassay (ECLIA) method. Results The measurement range of the assay was 1-900 ng/mL, with a detection limit of 0.83 ng/mL. The inter-assay and intra-assay imprecision were 4.67% and 5.38% with high concentration samples, and 9.27% and 17.64% with low concentration samples, respectively. The cross-reactivity (%) for different antigens was less than 0.05%, and the recovery was between 94% and 108%. Percentage deviation of all the dilutions was less than 12.5% during linearity estimation. The interference bias caused by different substances was less than 10%. The reference interval of the assay was 0-4.442 ng/mL. Comparison with the commercial ECLIA method for clinical sample detection, the proposed method showed a correlation of 0.9878 and no significant differences between the methods were observed (p = 0.6666). Conclusions The ICP-MS based immunoassay was successfully developed, and the analytical performance of the assay met the requirements of the CLSI, which fully proved the clinical transferability and application of the new method.
引用
- Jiang W, Sun G, Wen X, et al. Development and evaluation of an element-tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection: can we apply the new assay in the clinical laboratory? Clin Chem Lab Med. 2020. PMID: 31639100. doi:10.1515/cclm-2019-0566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。